千金药业(600479) - 2019 Q1 - 季度财报

Financial Performance - Operating income rose by 16.48% to CNY 804,063,401.00 year-on-year[6] - Net profit attributable to shareholders increased by 43.18% to CNY 40,637,650.72 compared to the same period last year[6] - Basic earnings per share increased by 28.48% to CNY 0.1042[6] - The weighted average return on equity improved by 0.34 percentage points to 2.13%[6] - Total operating revenue for Q1 2019 reached ¥804,063,401, an increase of 16.5% compared to ¥690,326,657 in Q1 2018[37] - Net profit for Q1 2019 was ¥53,944,808, representing a 27.3% increase from ¥42,422,125 in Q1 2018[38] - Earnings per share for Q1 2019 were ¥0.1042, compared to ¥0.0811 in Q1 2018, reflecting a growth of 28.8%[38] - Operating profit for Q1 2019 was CNY 25,068,346.95, an increase of 13.7% from CNY 22,054,589.45 in Q1 2018[40] Cash Flow - Cash flow from operating activities surged by 133.28% to CNY 48,074,675.33 year-on-year[6] - The company's cash flow from operating activities increased by 133.28%, reaching ¥48,074,675.33 compared to ¥20,607,771.58 in the previous period[24] - Operating cash inflow for Q1 2019 was CNY 335,297,155.54, an increase of 35.2% compared to CNY 248,038,516.73 in Q1 2018[45] - Net cash flow from operating activities decreased to CNY 5,213,209.94 from CNY 54,078,606.91 year-over-year, representing a decline of 90.3%[46] - Cash inflow from investment activities totaled CNY 301,583,985.26, compared to CNY 125,182,738.21 in Q1 2018, indicating a growth of 141.5%[44] - Investment cash inflow for Q1 2019 was CNY 299,543,146.90, significantly higher than CNY 122,567,330.75 in Q1 2018, marking an increase of 144.4%[46] - Net cash flow from investing activities improved to CNY 86,551,712.02 from a negative CNY 135,815,682.63 year-over-year[46] Assets and Liabilities - Total assets increased by 6.12% to CNY 3,685,166,836.74 compared to the end of the previous year[6] - The company's current assets reached CNY 2,789,132,694.78, up from CNY 2,596,320,070.99 at the end of 2018, indicating an increase of about 7.4%[28] - Total liabilities increased to CNY 1,180,629,796.13 from CNY 1,042,523,613.03, representing a rise of about 13.2%[30] - The company's equity attributable to shareholders rose to CNY 2,093,112,075.69 from CNY 2,028,833,840.59, indicating an increase of approximately 3.2%[30] - The total liabilities as of Q1 2019 amounted to ¥361,021,766, a slight decrease from ¥369,283,728 in the previous year[34] - Total liabilities amounted to CNY 1,042,523,613.03, with current liabilities at CNY 955,927,049.89 and non-current liabilities at CNY 86,596,563.14[49] Shareholder Information - The total number of shareholders reached 32,394 at the end of the reporting period[12] - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group, holds 28.53% of the shares[12] Research and Development - Research and development expenses grew by 42.18%, amounting to ¥19,168,032.20 compared to ¥13,481,465.45 in the same period last year[21] - Research and development expenses increased to ¥19,168,032, up 42.3% from ¥13,481,465 in Q1 2018[37] - Research and development expenses increased to CNY 8,347,231.84, representing a rise of 6.6% from CNY 7,832,351.11 in Q1 2018[40] Other Financial Metrics - Government subsidies recognized in the current period amounted to CNY 2,630,214.55[9] - Non-recurring gains and losses totaled CNY 2,970,228.88 for the reporting period[9] - The company reported a significant increase in other receivables, which rose to CNY 142,462,201.13 from CNY 61,673,500.09, representing a growth of approximately 130%[28] - The company reported a financial cost of -¥6,157,881 in Q1 2019, which is an increase in income compared to -¥3,356,346 in Q1 2018[37] - The company recorded a financial expense of CNY -7,398,930.81, compared to CNY -4,562,303.57 in Q1 2018, indicating a worsening in financial costs[40] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[39]